TY - JOUR
T1 - Association between prefrontal N-acetylaspartate and insight in psychotic disorders
AU - Larabi, Daouia I.
AU - Liemburg, Edith
AU - Pijnenborg, Gerdina H.M. Pijnenborg
AU - Sibeijn-Kuiper, Anita
AU - de Vos, Annerieke E.
AU - Bais, Leonie
AU - Knegtering, Henderikus
AU - Curcic-Blake, Branisalava
AU - Aleman, Andre
PY - 2017/1
Y1 - 2017/1
N2 - Insight is impaired in most patients with psychosis and has been associated with poorer prognosis. The exact neural basis of impaired insight is still unknown, but it may involve disrupted prefrontal neural connectivity. Numerous studies have indeed found white matter (WM) abnormalities in psychosis. The association between prefrontal WM abnormalities and insight has not been studied yet by means of proton magnetic resonance spectroscopy (H-1-MRS). H-1-MRS can be used to measure N-acetylaspartate (NAA), which is considered to be a marker of neuronal integrity. We measured insight with the Birchwood Insight Scale (BIS) as well as item G12 of the Positive and Negative Syndrome Scale (PANSS) in 88 patients with psychosis. Prefrontal WM concentrations of NAA and ratios of NAA to creatine (Cr) were assessed with H-1-MRS. Nonparametric partial correlational analyses were conducted between NAA concentrations and insight controlling for illness duration, standardized antipsychotic dose, symptom scores, voxel grey matter content and voxel cerebrospinal fluid content. We found a significant correlation between reduced NAA/Cr ratios and poorer insight as measured with the BIS, which remained significant after additional correction for full width at half maximum, signal/noise and age. This is the first study reporting a relationship between lower prefrontal concentrations of a marker of neuronal integrity and impaired insight, providing further evidence that prefrontal pathology may play an important role in impaired insight in psychosis. This may be explained by the involvement of the prefrontal cortex in several executive and metacognitive functions, such as cognitive flexibility and perspective taking. (C) 2016 Elsevier B.V. All rights reserved.
AB - Insight is impaired in most patients with psychosis and has been associated with poorer prognosis. The exact neural basis of impaired insight is still unknown, but it may involve disrupted prefrontal neural connectivity. Numerous studies have indeed found white matter (WM) abnormalities in psychosis. The association between prefrontal WM abnormalities and insight has not been studied yet by means of proton magnetic resonance spectroscopy (H-1-MRS). H-1-MRS can be used to measure N-acetylaspartate (NAA), which is considered to be a marker of neuronal integrity. We measured insight with the Birchwood Insight Scale (BIS) as well as item G12 of the Positive and Negative Syndrome Scale (PANSS) in 88 patients with psychosis. Prefrontal WM concentrations of NAA and ratios of NAA to creatine (Cr) were assessed with H-1-MRS. Nonparametric partial correlational analyses were conducted between NAA concentrations and insight controlling for illness duration, standardized antipsychotic dose, symptom scores, voxel grey matter content and voxel cerebrospinal fluid content. We found a significant correlation between reduced NAA/Cr ratios and poorer insight as measured with the BIS, which remained significant after additional correction for full width at half maximum, signal/noise and age. This is the first study reporting a relationship between lower prefrontal concentrations of a marker of neuronal integrity and impaired insight, providing further evidence that prefrontal pathology may play an important role in impaired insight in psychosis. This may be explained by the involvement of the prefrontal cortex in several executive and metacognitive functions, such as cognitive flexibility and perspective taking. (C) 2016 Elsevier B.V. All rights reserved.
KW - Proton magnetic resonance spectroscopy (H-1-MRS)
KW - Neuronal pathology
KW - White matter
KW - Connectivity
KW - Executive functions
KW - MAGNETIC-RESONANCE-SPECTROSCOPY
KW - WHITE-MATTER
KW - 1ST-EPISODE SCHIZOPHRENIA
KW - COGNITIVE INSIGHT
KW - METABOLITE CONCENTRATIONS
KW - NEGATIVE SYMPTOMS
KW - CORTEX
KW - DYSFUNCTION
KW - BRAIN
KW - METAANALYSIS
U2 - 10.1016/j.schres.2016.09.018
DO - 10.1016/j.schres.2016.09.018
M3 - Article
SN - 0920-9964
VL - 179
SP - 112
EP - 118
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -